AU2020902550A0 - Compositions and methods for treating disorders associated with loss-of-function mutations in SCN2A - Google Patents
Compositions and methods for treating disorders associated with loss-of-function mutations in SCN2AInfo
- Publication number
- AU2020902550A0 AU2020902550A0 AU2020902550A AU2020902550A AU2020902550A0 AU 2020902550 A0 AU2020902550 A0 AU 2020902550A0 AU 2020902550 A AU2020902550 A AU 2020902550A AU 2020902550 A AU2020902550 A AU 2020902550A AU 2020902550 A0 AU2020902550 A0 AU 2020902550A0
- Authority
- AU
- Australia
- Prior art keywords
- scn2a
- compositions
- loss
- methods
- disorders associated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 102100020050 SCN2A Human genes 0.000 title 1
- 101700036324 SCN2A Proteins 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 230000004777 loss-of-function mutation Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Priority Applications (15)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA3186629A CA3186629A1 (en) | 2020-07-22 | 2021-07-22 | Compositions and methods for treating disorders associated with loss-of-function mutations in scn2a |
| PCT/AU2021/050788 WO2022016222A1 (en) | 2020-07-22 | 2021-07-22 | Compositions and methods for treating disorders associated with loss-of-function mutations in scn2a |
| PE2023000101A PE20230982A1 (en) | 2020-07-22 | 2021-07-22 | COMPOSITIONS AND METHODS TO TREAT DISORDERS ASSOCIATED WITH LOSS OF FUNCTION MUTATIONS IN SCN2A |
| US18/005,800 US20230272387A1 (en) | 2020-07-22 | 2021-07-22 | Compositions and methods for treating disorders associated with loss-of-function mutations in scn2a |
| MX2023000907A MX2023000907A (en) | 2020-07-22 | 2021-07-22 | Compositions and methods for treating disorders associated with loss-of-function mutations in scn2a. |
| IL299999A IL299999A (en) | 2020-07-22 | 2021-07-22 | Compositions and methods for treating disorders associated with loss-of-function mutations in SCN2A |
| JP2023504330A JP2023534720A (en) | 2020-07-22 | 2021-07-22 | Compositions and methods for treating disorders associated with loss-of-function mutations in SCN2A |
| CN202180064122.5A CN116368227A (en) | 2020-07-22 | 2021-07-22 | Compositions and methods for treating disorders associated with loss of function mutations in SCN2A |
| BR112023000988A BR112023000988A2 (en) | 2020-07-22 | 2021-07-22 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH LOSS OF FUNCTION MUTATIONS IN SCN2A |
| EP21845305.8A EP4185697A1 (en) | 2020-07-22 | 2021-07-22 | Compositions and methods for treating disorders associated with loss-of-function mutations in scn2a |
| KR1020237005996A KR20230095056A (en) | 2020-07-22 | 2021-07-22 | Compositions and methods for treating disorders associated with loss-of-function mutations in SCN2A |
| AU2021311137A AU2021311137A1 (en) | 2020-07-22 | 2021-07-22 | Compositions and methods for treating disorders associated with loss-of-function mutations in SCN2a |
| CL2023000208A CL2023000208A1 (en) | 2020-07-22 | 2023-01-20 | Compositions and methods for treating disorders associated with loss-of-function mutations in scn2a |
| CONC2023/0001922A CO2023001922A2 (en) | 2020-07-22 | 2023-02-21 | Compositions and methods for treating disorders associated with loss-of-function mutations in scn2a |
| ECSENADI202312641A ECSP23012641A (en) | 2020-07-22 | 2023-02-22 | COMPOSITIONS AND METHODS TO TREAT DISORDERS ASSOCIATED WITH LOSS OF FUNCTION MUTATIONS IN SCN2A |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2020902550A0 true AU2020902550A0 (en) | 2020-08-06 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4042783A4 (en) | Methods and apparatuses for cot sharing in unlicensed spectrum | |
| EP3829635A4 (en) | Muscle-targeting complexes and uses thereof in treating muscle atrophy | |
| EP3740073A4 (en) | Materials and methods for treating bacterial infections in plants | |
| EP3850060A4 (en) | Crosslinkable aromatic polymer compositions for use in additive manufacturing processes and methods for forming the same | |
| WO2010065491A3 (en) | Methods of treating inflammatory disorders | |
| ZA202104676B (en) | Compositions and methods for treating hemoglobinopathies | |
| EP3598879A4 (en) | Methods and devices for processing certificates in blockchain system | |
| EP3860619A4 (en) | Compositions and methods for the treatment of pathogenic infections in plants | |
| EP3920898A4 (en) | Methods and compositions for treating sleep apnea | |
| EP3917622A4 (en) | Compositions and methods for treating anxiety-related disorders | |
| EP3931336A4 (en) | Compositions and methods for treating laminopathies | |
| EP3870154A4 (en) | Compositions and methods for preventing and treating antibiotic induced pathologies using probiotics in the biofilm state | |
| EP4096675A4 (en) | Compositions and methods for treating long covid | |
| EP3344640A4 (en) | Aminoglycoside derivatives and uses thereof in treating genetic disorders | |
| EP3350194A4 (en) | Aminoglycoside derivatives and uses thereof in treating genetic disorders | |
| EP3990119A4 (en) | Methods and compositions comprising brd9 activating therapies for treating cancers and related disorders | |
| EP3924478A4 (en) | Compositions and methods for treating glycogen storage disease type 1a | |
| MX2021013068A (en) | High density lipoprotein nanoparticles and rna templated lipoprotein particles for ocular therapy. | |
| EP3775217A4 (en) | Microrna-based compositions and methods used in disease treatment | |
| EP3400232A4 (en) | Aminoglycoside derivatives and uses thereof in treating genetic disorders | |
| EP4157290A4 (en) | Compositions, their uses in therapy and methods thereof | |
| AU2020902550A0 (en) | Compositions and methods for treating disorders associated with loss-of-function mutations in SCN2A | |
| AU2020901507A0 (en) | Compositions and methods for treating disorders associated with loss-of-function mutations in SYNGAP1 | |
| IL299999A (en) | Compositions and methods for treating disorders associated with loss-of-function mutations in SCN2A | |
| EP3781262A4 (en) | Compositions and methods for treating cardiovascular disease in selected patients |